Axim Biotechnologies Inc (OTCMKTS: AXIM) Announces it Has Created Second Rapid Antibody Test for COVID-19

Axim Biotechnologies Inc (OTCMKTS: AXIM) has announced that it has created a second-generation Rapid Antibody Neutralizing Test for COVID-19. The test is known as ImmunoPass.

T cells and antiviral antibodies take part in protection from COVID-19. However, T cells are more challenging to measure than antibodies that people can measure from a drop of blood. AXIM’s first rapid test, NeuCovix, is under review by the U.S Food and Drug Administration (FDA), can measure the amount of neutralizing antibodies. These antibodies prevent people from getting infected by COVID-19 if their levels in the blood are high.

Test can tell if a patient is responding to the vaccine

COVID-19 vaccines work by triggering antibodies that protect against the virus. However, this does not always work as not all these antibodies can neutralize the COVID-19 virus. The second AXIM test goes a step further by identifying antibodies that bind to the virus without neutralizing it and those that do.

The test is essential as COVID-19 vaccines might not produce high amounts of neutralizing antibodies in everyone. The second AXIM test can tell people if they are responding appropriately to a vaccine. It also provides a quantitative analysis of their neutralizing antibodies.

According to the CEO of AXIM Biotech, John W. Huemoeller II, the test is essential as it tells recipients if they are responding well to the vaccine in about 10 minutes. People want to stay uninfected to avoid transmitting the virus to vulnerable populations.

Work done by AXIM

AXIM Biotechnologies is a vertically integrated preclinical stage research and development (R&D) company that deals in the diagnosis of oncological indications, dry eye disease (DED), and SARS CoV-2 (COVID-19). The company’s first COVID-19 neutralizing antibody test is the first to measure levels of neutralizing antibodies that protect from COVID-19 infection.

The company is developing other tests to enable the early diagnosis of DED and cancer. It is also developing small molecule drugs to block metastasis and treat cancer. AXIM is developing SPX-1009, an anti-metastatic drug that measures the amount of quiescent sulfhydryl oxidase I.

The company started on November 18, 2010, before changing its name from Axim International Inc in July 2014. It has its headquarters in San Diego, California.